Australian researchers are developing next-generation iron-based nanoparticles to improve treatment for triple-negative breast cancer (TNBC). This aggressive cancer lacks protein targets, making conventional therapies ineffective in treating cancer.
Scientists from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) aim to change that. Their innovative ‘nano-adjuvants’—particles so small that thousands fit on a single hair strand—could revolutionize breast cancer immunotherapy.
ENHANCING THE IMMUNE SYSTEM’S ATTACK ON CANCER
Current immunotherapy struggles to combat TNBC. The new nanoparticles boost T-cell activity, helping the immune system recognize and destroy cancer cells.
“Despite the promise of immunotherapy, its effectiveness against TNBC remains extremely limited,” said Prof. Yu Chengzhong from AIBN. “Our research aims to change that in the battle against breast cancer.”
A MAJOR RESEARCH INVESTMENT
This five-year project, backed by a A$3 million ($1.89 million USD) National Health and Medical Research Council grant, could lead to clinical applications for other hard-to-treat cancers, including ovarian cancer.
AIBN Director Alan Rowan highlighted the study’s groundbreaking nature.
“This research will push scientific boundaries. It offers hope to women facing devastating outcomes from breast cancer.”
THE FUTURE OF CANCER TREATMENT
With over two decades of nanomedicine expertise, researchers believe iron-based nanoparticles could reshape cancer treatment. If successful, this breakthrough could pave the way for safer, more effective therapies for TNBC and beyond.
